Table 1.
Baseline clinicopathological characteristics.
| Discovery set (N = 18) | Validation set (N = 56) | P value | |
|---|---|---|---|
| Median age in years (range) | 64 (34–64) | 65 (39–81) | 0.874 |
| Sex | 0.364 | ||
| Male | 15 (83.3%) | 39 (69.6%) | |
| Female | 3 (16.7%) | 17 (30.4%) | |
| Smoking history | 0.155 | ||
| Never smoker | 3 (16.7%) | 20 (35.7%) | |
| Current/former smoker | 15 (83.3%) | 36 (64.3%) | |
| ECOG performance status | 0.927 | ||
| ≤1 | 16 (88.9%) | 49 (87.5%) | |
| >1 | 2 (11.1%) | 7 (12.5%) | |
| Number of previous treatments | |||
| ≤2 | 12 (66.6%) | 33 (58.9%) | |
| >2 | 6 (33.4%) | 26 (41.9%) | |
| Histology | 0.129 | ||
| Adenocarcinoma | 9 (50%) | 39 (69.6%) | |
| Squamous cell carcinoma | 9 (50%) | 17 (30.4%) | |
| PD-L1 positivity | 0.023 | ||
| Positive | 6 (33.3%) | 44 (78.6%) | |
| Negative | 10 (55.6%) | 12 (21.4%) | |
| N/A | 2 (11.1%) | 0 (0%) | |
| Driver mutation for target therapy | 0.589 | ||
| EGFR mutation | 2 (11.1%) | 11 (19.6%) | |
| ALK rearrangement | 0 (0%) | 1 (1.8%) | |
| Types of drug | 0.097 | ||
| Nivolumab | 17 (94.4%) | 41 (73.2%) | |
| Pembrolizumab | 1 (5.6%) | 15 (26.8%) | |
ECOG Eastern Cooperative Oncology Group, N/A not available.